novel coronavirus pneumonia (COVID-19)
Conditions
Interventions
experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination
Historical Control:LPV/r
Sponsors
Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. diagnosis of 2019-new coronavirus (2019-nCoV) pneumonia; 2. adult patients aged 18-80 years old.
Exclusion criteria
Exclusion criteria: 1. ARDS was developed after infection without antiviral treatment; 2. suffering from HBV, HIV, pancreatitis, intrahepatic bile duct stones or having the previous history mentioned above ; 3. severe heart, liver, kidney and respiratory diseases before infection; 4. history of metabolic and endocrine diseases such as osteoporosis; 5. pregnant or nursing women; 6. those who are unable to cooperate in mental state, suffer from mental disease, have no self-control and cannot express clearly; 7. participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Viral nucleic acid turns negative time;Develop into ARDS patient rate;length of hospital stay; | — |
Countries
China
Contacts
Public ContactJiang Hua
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Outcome results
None listed